(Q38057813)

27 August 2017

Activin receptor antagonists for cancer-related anemia and bone disease (English)

1 reference

27 August 2017

cancer-related anemia

1 reference

Scott Z Fields

1

1 reference

27 August 2017

Shiroo Parshad

2

1 reference

27 August 2017

Madhurima Anne

3

1 reference

27 August 2017

Haralambos Raftopoulos

4

1 reference

27 August 2017

Mark J Alexander

5

1 reference

27 August 2017

Matthew L Sherman

6

1 reference

27 August 2017

Abderrahmane Laadem

7

1 reference

27 August 2017

Victoria Sung

8

1 reference

27 August 2017

Evangelos Terpos

9

1 reference

27 August 2017

language of work or name

English

0 references

publication date

6 November 2012

1 reference

Expert Opinion on Investigational Drugs

27 August 2017

1 reference

27 August 2017

22

1 reference

27 August 2017

1

1 reference

27 August 2017

87-101

1 reference

Activin A and bone metastasis

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Chemotherapy-induced anemia in adults: incidence and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

The silent risks of blood transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Anemia management in oncology and hematology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

TGFbeta signalling: a complex web in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Inhibin is an antagonist of bone morphogenetic protein signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

New insights into the mechanisms of activin action and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Repulsive guidance molecule RGMa alters utilization of bone morphogenetic protein (BMP) type II receptors by BMP2 and BMP4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

The transforming growth factor-beta superfamily of receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Multiple defects and perinatal death in mice deficient in follistatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Bone morphogenetic proteins and their antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Betaglycan: a multifunctional accessory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Complex and context dependent regulation of hematopoiesis by TGF-beta superfamily signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

BMP4 regulates the hematopoietic stem cell niche

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Stress erythropoiesis: new signals and new stress progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Selective and indirect modulation of human multipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Activin A: a commitment factor in erythroid differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

In vivo treatment with erythroid differentiation factor (EDF/activin A) increases erythroid precursors (CFU-E and BFU-E) in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

The role of activin a in regulation of hemopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Follicle-stimulating hormone increases bone mass in female mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Follistatin as a potent regulator of bone metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Bone morphogenetic protein and bone metastasis, implication and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Adenovirus-mediated overexpression of follistatin enlarges intact liver of adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Activin A: an autocrine inhibitor of initiation of DNA synthesis in rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Functional analysis of activins during mammalian development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Activin betaC and betaE genes are not essential for mouse liver growth, differentiation, and regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Activin C antagonizes activin A in vitro and overexpression leads to pathologies in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

The activin axis in liver biology and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Truncated activin type I receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Overexpression of activin A in stage IV colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Serum and tissue expression of activin a in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Functional improvement of dystrophic muscle by myostatin blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Antagonism of activin by activin chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Generation of a specific activin antagonist by modification of the activin A propeptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Activin and inhibin binding to the soluble extracellular domain of activin receptor II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

A soluble activin type IIA receptor induces bone formation and improves skeletal integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Strategies for TGF-beta modulation: a review of recent patents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

The specificities of small molecule inhibitors of the TGFß and BMP pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

Multiple myeloma: most common end-organ damage and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

A truncated activin receptor inhibits mesoderm induction and formation of axial structures in Xenopus embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.738666

10.1517/13543784.2013.738666

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference